To utilize the synergistic interactions between TLR2 and TLR9, the cervical cancer tumor antigen E7 was combined with TLR2/TLR9 agonists to reverse the immunosuppressive tumor microenvironment in TC-1 tumors. The gene discussed is TLR2; the disease is neoplasm.